Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Atreca Inc BCEL

Alternate Symbol(s):  COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human... see more

Bullboard (PINL:BCEL)

View:
Post by Iseneschalon Oct 19, 2023 1:47pm

BCEL ....N.H.O.D

Where will this go to ??? Cheers !
Post by Iseneschalon Oct 19, 2023 1:18pm

BCEL.....2nd day runner?

Sheesh.....Just because Bill & Linda Gates are involved  ; )
Post by longon01on Mar 05, 2023 7:47am

Atreca 12 month Price Target between 10$ & 25$

Are the 3 stock price forecasters credible? When the stock is at the 1.40$ mark. If so, why are investors not buying way more of this company? Seems odd All feedback is welcome.  Thank you ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities